arrow
A

Asunción Hernando

university hospital 12 de octubre
H指数:23
被引数:1,522

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL)

多替拉韦/拉米夫定与比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺在病毒载量极高(≥500000 copies/mL)的HIV感染者中的疗效比较

2026-08-210
PRE
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002-2023)

2002年至2023年西班牙人类免疫缺陷病毒感染者中丙型肝炎病毒感染流行趋势

2025-09-013
PRE
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO) (vol 55, 102779, 2020)
2023-03-011
OAAI
Comparison of the Accuracy of the 7-Item HADS Depression Subscale and 14-Item Total HADS for Screening for Major Depression: A Systematic Review and Individual Participant Data Meta-Analysis

7项HADS抑郁子量表和14项总HADS筛查重度抑郁症的准确性比较: 系统评价和个体参与者数据荟萃分析

2023-02-019
OA
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
2022-11-086
OAAI
Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)
2021-08-306
PRE
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study
2020-11-1725
PREAI
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)
2020-05-0128
OAAI
Risk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21
2020-03-1114
OAAI
Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant
2018-01-1221
OAAI